Meeting Banner
Abstract #2937

Cerebral metabolite biomarkers of Type 2 Diabetes Mellitus, blood glucose measures, and cognitive decline

Frank C.G. van Bussel 1 , Walter H. Backes 1 , Paul A.M. Hofman 1 , Alfons G.H. Kessels 2 , Nicolaas A.J. Puts 3 , Richard A.E. Edden 3 , Tamar M. van Veenendaal 1 , Harm J. van de Haar 1 , Martin P.J. van Boxtel 4 , Miranda T. Schram 5 , Coen D.A. Stehouwer 5 , Joachim E. Wildberger 1 , and Jacobus F.A. Jansen 1

1 Radiology, Maastricht University Medical Center, Maastricht, Netherlands, 2 Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, Netherlands, 3 Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 4 Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, Netherlands, 5 Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands

Type 2 Diabetes Mellitus (T2DM) is associated with cerebral abnormalities, accelerated cognitive decline, and dementia. T2DM risk factors such as blood glucose levels are associated with developing of dementia. Magnetic resonance spectroscopy provides the opportunity to study cerebral metabolites. Altered cerebral metabolic concentrations may be associated with neurodegeneration. The aim of this study is to examine if cerebral metabolites constitute a MRI biomarker for i) T2DM, ii) blood glucose measures, and/or iii) cognitive status. This study is the first study to report higher GABA+ levels in subjects with poor blood glucose control. Unfortunately, no relationship with cognitive status was observed.

This abstract and the presentation materials are available to members only; a login is required.

Join Here